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SUMMARY
High plasma HDL-cholesterol (HDL-c) is a well-established protective factor in cor-
onary artery disease (CAD). One of its potential protective mechanisms is the inhibition
of the cytokine-induced upregulation of expression of cellular adhesion molecules
(CAMs). High sCAM levels were found to be associated with low HDL-c in some studies
performed mostly in hyperlipidemic subjects, but this association has not yet been inves-
tigated in CAD patients. In addition, conflicting results were obtained from in vitro stud-
ies that explored the proposed HDL effect on cytokine-induced CAM expression. The aim
of the present case-control study was to investigate whether low HDL-c values are asso-
ciated with CAM overexpression in normolipidemic CAD patients and healthy individu-
als, matched according to age and gender. Plasma HDL-c, sICAM-1, sVCAM-1, and sE-
selectin were measured in 37 normolipidemic patients with angiographically verified cor-
onary artery disease and in 52 healthy normolipidemic subjects. The sCAM values
obtained in the subjects (patients or controls) with low HDL-c levels (< 1.03 mmol/L)
were compared with the values in the subjects with high HDL-c (≥ 1.03 mmol/L). No sig-
nificant difference was found between sICAM-1, sVCAM-1, and E-selectin values
obtained in subjects with low and high HDL-c, either among the patients or the healthy
controls. In conclusion, low HDL-c levels are not associated with CAM overexpression
in normolipidemic CAD patients and healthy subjects.  (Int Heart J 2005; 46: 593-600)
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INCREASED leukocyte adhesion to the vascular endothelium and their transen-
dothelial migration are early events in atherogenesis, mediated by cellular adhe-
sion molecules (CAMs): intercellular adhesion molecule-1 (ICAM-1), vascular
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cell adhesion molecule-1 (VCAM-1), and E-selectin.1) Membrane bound CAMs
are expressed on endothelial cells, smooth muscle cells, and tissue macroph-
ages.2,3) Their soluble forms, sICAM-1, sVCAM-1, and sE-selectin circulate in
plasma, and the sCAM plasma levels are correlated with CAM expression on the
endothelial cell membrane.4)
A high plasma HDL-cholesterol (HDL-c) level is an established protective
factor in coronary artery disease (CAD).5) There is evidence that the protective
effect of HDL is not achieved solely by its role in reverse cholesterol transport,
but also by several other mechanisms, including its antioxidative and antiinflam-
matory activities.6) The cytokine-induced upregulation of CAM expression was
reported to be inhibited by HDL,7) and high circulating sCAM levels were shown
to be associated with low HDL-c in several studies performed in different set-
tings.8-10) In the present study, we investigated the relationship between HDL-c
and sCAM (sICAM-1, sVCAM-1 and sE-selectin) levels in normolipidemic
CAD patients and healthy individuals who were matched according to age and
gender.
METHODS
Study population: A group consisting of 37 patients with angiographically estab-
lished CAD with ≥ 50% of luminal narrowing was formed out of a larger group
of 100 patients referred to the Institute of Cardiovascular Disease, Clinical Centre
of Serbia, Belgrade, by using the following exclusion criteria: LDL-c ≥ 4.13
mmol/L and/or triglycerides ≥ 2.25 mmol/L, presence of liver or kidney disease,
diabetes mellitus, obesity (body mass index [BMI] > 30 kg/m2), history of alcohol
abuse, or drug treatments known to affect plasma sCAMs levels. Angiograms
were reviewed by two cardiologists who were not aware that a patient was
enrolled in the study. The control group consisted of 52 healthy blood donors who
met the same criteria used for patient selection. The study was planned according
to the ethical guidelines of the Declaration of Helsinki. According to institutional
guidelines, the protocol was approved by the local institutional review commit-
tee, and informed consent was obtained from each subject involved in the study.
Apparatus, reagents, and procedures: Blood samples were collected into evacu-
ated tubes containing EDTA, citrate or serum separator gel, after a 12 hour fasting
period. Plasma and serum were separated and multiple aliquots of each sample
were stored at -80°C. The samples were thawed immediately before analyses.
HDL-cholesterol was measured by an enzymatic method using a Hitachi
704 analyzer and reagents (Roche Diagnostics, Mannheim, Germany) after pre-
cipitation of the EDTA plasma with phosphotungstic acid in the presence of mag-
nesium ions. Circulating cellular adhesion molecules (sICAM, sVCAM, and sE-
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selectin) were assayed using the ELISA technique with a Parameter Colorimetric
Sandwich ELISA (R&D Systems, Minneapolis, USA) as recommended by the
manufacturer and a BIOMEK 1000 Automated Laboratory Work Station (Beck-
mann Instruments, Inc., Fullerton, CA, USA). Serum hs-CRP levels were assayed
using a latex-enhanced immunoturbidimetric method with a Quantex hs-CRP kit
(BIOKIT, Barcelona, Spain) and ILAB 600 analyzer (International Laboratory,
Milan, Italy). Fibrinogen was measured in citrate plasma by the Clauss method
with ACL 200 (International Laboratory, Milan, Italy) and the original reagents.
Total cholesterol, triglyceride, LDL-cholesterol, apolipoprotein AI, and apolipo-
protein B concentrations were also measured using standard laboratory proce-
dures.
Statistical methods: Unless otherwise specified, data are presented as the mean ±
SD, or frequency percentages. Statistical testing of differences in the continuous
variables between the groups was performed using Student's t test for normally
distributed variables. Because the distributions of the triglyceride and hs-CRP
values were skewed, a log transformation was conducted and the values obtained
were compared. For these parameters, the median values are also presented. For
categorical variables, group differences were examined using 2 × 2 contingency
tables and χ2 test of significance. Group differences with P < 0.05 were consid-
ered statistically significant. Correlations between sCAM and HDL-c values
were also examined by Spearman regression analysis.
RESULTS
Based on the results of the HDL-c measurements, both the patients and
healthy controls were divided into two groups to give a total of four groups: CAD
patients with HDL-c < 1.03 mmol/L, CAD patients with HDL-c ≥ 1.03 mmol/L,
controls with HDL-c < 1.03 mmol/L, and controls with HDL-c ≥ 1.03 mmol/L.
The demographic characteristics and the concentrations of circulating lipid
profile parameters, hs-CRP, and fibrinogen in the patients and healthy subjects
with low and high HDL-c are shown in Table I. The results are reported as the
mean ± SD, or frequency percentages. Medians are also shown for triglycerides
and hs-CRP, because of their skewed distributions. As expected, triglycerides
were higher and apo A-I lower in the low HDL-c groups. Significantly higher hs-
CRP levels were obtained in the patients than in the healthy controls, both in the
low HDL-c and high HDL-c groups. The concentration of hs-CRP was lower in
the subjects with higher HDL-c, but only in the group of healthy controls. A
greater proportion of smokers was found in the CAD patients. The proportions of
the patients receiving aspirin or ACE inhibitors are also shown, and they were not
significantly different between the groups with different HDL-c levels. As only
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normolipidemic patients were included in the study, none received lipid-lowering
drugs.
The sCAM levels did not differ significantly between the patients receiving
ACE inhibitors or aspirin and the patients not treated with the drugs (P > 0.05 for
Table I. Demographic Characteristics and Laboratory Data of Normolipidemic CAD Patients and Healthy Subjects
Divided According to Their HDL-c Levels
Control group (n = 52) Patient group (n = 37)
Variable HDL-c < 1.03 mmol/L HDL-c ≥ 1.03 mmol/L HDL-c < 1.03 mmol/L HDL-c ≥ 1.03 mmol/L
n
n (males)/n (females)
Age, years
BMI, kg/m2 
SBP, mmHg
DBP, mmHg
Cholesterol, mol/L
Triglycerides, mmol/L
HDL-cholesterol, mmol/L
LDL-cholesterol, mmol/L
Apo A-I, g/L
Apo B, g/L
hs-CRP, mg/L
Fibrinogen, g/L
Smokers, %
Aspirin treatment, %
ACE inhibitors treatment, %
16
15/1
48.0 ± 10.0
26.48 ± 2.14
136 ± 9
84 ± 7.3
4.78 ± 0.65
1.67 ± 0.49
(median: 1.81)
0.89 ± 0.13
3.14 ± 0.59
1.07 ± 0.19
1.32 ± 0.47
2.61 ± 2.77+ 
(median: 1.62)
4.77 ± 1.23
37.5 + 
-
-
36
22/14
52.0 ± 8.7
25.75 ± 3.63
140 ± 19
83 ± 8.7
5.7 ± 0.57 *
1.34 ± 0.48 *
(median: 1.34)
1.24 ± 0.1.16 * +
3.19 ± 0.43
1.49 ± 0.28 * + 
1.10 ± 0.26 * + 
1.03 ± 0.88* + 
(median: 0.66)
4.47 ± 1.22+ 
39 + 
-
-
17
12/5
49.4 ± 9.4
27.50 ± 2.39
132 ± 13
84 ± 8.3
4.83 ± 0.63
1.61 ± 0.35
(median: 1.62)
0.84 ± 0.14
3.26 ± 0.50
1.05 ± 0.20
1.59 ± 0.50
8.08 ± 15.41
(median: 2.59)
5.39 ± 1.63
59
23.5
41
20
12/8
54.5 ± 7.3
25.16 ± 3.22 *
141 ± 20
87 ± 11.3
5.20 ± 0.52
1.26 ± 0.35 *
(median: 1.15)
1.46 ± 0.33 *
3.40 ± 0.45
1.20 ± 0.22 *
1.38 ± 0.36
10.16 ± 18.88
(median: 2.87)
5.84 ± 1.76
60
20
50
SBP = systolic blood pressure; DBP = diastolic blood pressure. Values are given as means ± SD. *P < 0.05 for HDL-c ≥ 1.03 
mmol/L versus HDL-c < 1.03 mmol/L in control or patient groups; +P < 0.05 for HDL-c ≥ 1.03 mmol/L in control versus patient 
groups and HDL-c < 1.03 mmol/L in control versus patient groups.
Table II. Plasma Concentrations of sCAMs in Normolipidemic CAD Patients and Healthy Subjects Divided
According to Their HDL-c Levels
Control group (n = 52) Patient group (n = 37)
Variable HDL-c < 1.03 mmol/L
n = 16
HDL-c ≥ 1.03 mmol/L
n = 36
HDL-c < 1.03 mmol/L
n = 17
HDL-c ≥ 1.03 mmol/L
n = 20
sVCAM-1, µg/L
sICAM-1, µg/L
sE-selectin, µg/L
658.6 ± 270.21
297.1 ± 110.14
37.24 ± 15.35+ 
678.4 ± 328.90
280.1 ± 83.86
35.08 ± 23.32
758.7 ± 289.22
305.3 ± 124.25
24.76 ± 15.23
748.9 ± 268.58
253.1 ± 55.12
30.27 ± 19.29
Values are given as means ± SD. +P < 0.05 for HDL-c < 1.03 mmol/L in control versus patient groups.
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all three adhesion molecules measured: sICAM-1, sVCAM-1, and sE-selectin,
data not shown).
When we compared the plasma sCAM concentrations obtained in the sub-
jects with low versus subjects with high HDL-c levels, no statistically significant
differences between the sCAM values could be demonstrated either in the
patients or in the control group (Table II). The correlation between sCAM and
HDL-c values was also tested, but no significant correlation was found (P > 0.05
for all three sCAMs measured).
DISCUSSION
Inhibition of cytokine-induced expression of CAMs by HDL was proposed
to be one of several mechanisms of HDL protective function.8) Numerous genetic
and environmental factors have been shown to influence circulating sCAM lev-
els, including hypercholesterolemia, hypertriglyceridemia, smoking, hyperten-
sion, and diabetes mellitus.
Many studies have investigated the association of sCAMs with coronary
artery disease, as well as their potential significance as circulating markers of the
disease. To our knowledge, the influence of low HDL-c on sCAM concentrations
has not yet been studied in CAD patients. The present data show that sCAM con-
centrations in patients with angiographically established CAD and low HDL-c
levels did not differ from the values obtained in the patients with high HDL-c
(Table II). However, we also found no significant relationship between HDL-c
and sCAMs in healthy controls. This is in disagreement with the results of several
studies conducted by other authors in different settings, which reported the asso-
ciation of high sCAM with low HDL-c concentrations.8-10) This difference could
be attributed to the different study design and patient selection. In contrast with
our patients and control groups of normolipidemic subjects, Lupatelli, et al9) and
Abe, et al10) investigated the effect of low HDL-c on sCAM levels in hyperlipi-
demic subjects. Lupatelli, et al9) found that low HDL-c was associated with
higher sVCAM-1 and sICAM-1 levels, whereas Abe, et al10) observed an associ-
ation with three sCAMs: sVCAM-1, sICAM-1, and sE-selectin. However, Cala-
bresi, et al8) reported increased sICAM-1 and sE-selectin concentrations in both
normolipidemic and hyperlipidemic subjects with low plasma HDL-c values. The
difference between their findings and the results of the present study could only
be attributed to the different genetic and environmental backgrounds of the sub-
jects involved in the two studies.
The results of in vitro studies that investigated the inhibition of proinflam-
matory cytokine-induced expression of CAMs by HDL are also controversial.
Cockerill, et al11) demonstrated that HDL inhibits TNFα and IL-1β-induced
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expression of cellular adhesion molecules in cultured human umbilical cord vein
endothelial cells. However, Zhang, et al,12) reported that no inhibitory effect of
HDL on cytokine-induced CAM expression could be found in cultured human
aortic endothelial cells, which is consistent with the results of the present study.
Higher concentrations of acute phase proteins (hs-CRP and fibrinogen) were
found in the CAD patients than in the healthy controls, showing the presence of
an inflammatory reaction in coronary artery disease (Table I). The concentration
of hs-CRP, which is known to be a very sensitive marker of inflammation, was
lower in the healthy subjects with higher HDL-c (HDL-c ≥ 1.03 mmol/L). This
could be a consequence of the antiinflammatory activity of HDL. However, this
effect is lost in coronary artery disease, since no association between high HDL-
c and low hs-CRP values could be demonstrated in the CAD patients (Table I).
Several reports have appeared which studied the potential antiinflammatory
effects of aspirin, ACE inhibitors, and statins, as established pharmacotherapy in
patients with coronary artery disease.13-18) Although the antiinflammatory effects
of larger doses of aspirin are well-known, they are generally considered negligi-
ble at low doses commonly used in CAD patients, and the beneficial effects of
aspirin are currently linked to suppression of thromboxane A2-dependent platelet
aggregation.13,14) ACE inhibitors were shown to reduce inflammation, not only by
inhibiting angiotensin II formation, but also by several angiotensin II-indepen-
dent mechanisms.14,16) The potential antiinflammatory activity of statins was
explained by the inhibition of nuclear factor-κB, a pivotal transcription factor
regulating the expression of a variety of inflammatory genes, which leads to the
reduced synthesis of inflammatory cytokines.14) In our study, a substantial propor-
tion of the CAD patients were treated with aspirin or ACE inhibitors (Table I).
The proportions of the patients receiving ACE inhibitors and aspirin were similar
in the high HDL-c and low HDL-c groups, and the levels of all three sCAMs mea-
sured in the patients receiving the drugs and the patients without therapy were not
significantly different, therefore, we were unable to prove any association
between either HDL-c or sCAM levels and therapy with ACE inhibitors or aspi-
rin. We were not able to examine the possible effects of statins, since only normo-
lipidemic patients were included in our study.
Because of the large interindividual variations in sCAM concentrations
obtained in the present study (Table II), as well as by other authors,9,17) a larger
number of subjects should be included in the study to improve the significance of
the results. However, coronary angiography is an invasive method that is not per-
formed widely and without a good reason. In addition, since hyperlipidemia is a
well-known risk factor for CAD, a large proportion of the patients undergoing
coronary angiography were hyperlipidemic, and only normolipidemic subjects
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were studied to exclude the effects of hyperlipidemia on sCAM concentrations.
These two factors significantly reduced the number of patients in the study.
We do agree with recent reports18,19) that, although endothelial dysfunction is
an important feature in early as well as in advanced stages of atherosclerosis, we
can not advocate its routine assessment by measuring soluble CAMs. As sug-
gested,19) certain aspects of laboratory limitations and costs need to be addressed
as well. To conclude, low HDL-c is not associated with CAM overexpression in
normolipidemic CAD patients and healthy individuals, but further studies with
greater numbers of subjects are needed to draw definite conclusions and elucidate
completely the relationship between HDL and cellular adhesion molecules.
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